Table 1.
Summary of recent clinical trials using MSCs for ischemic stroke.
| Reference | Disease | Source | Number | Mean Age (Range), Year | Route of Administration | Number of Cells | Number of Treatments | Results | Adverse Events | |
|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | |||||||||
| Chung et al. [48] | Ischemic stroke (Phase 3) |
BM | 39 | 15 | 68 (28–83) |
IV | 1 × 106/kg | 1 | Lower extremity motor functional recovery after 3 months |
No |
| Bhasin et al. [49] | Ischemic stroke | BM | 6 | 6 | 42.8 (20–60) |
IV | 5–6 × 107 cells | 1 | Improvement in the activities of daily living (ADL) after 156 and 208 weeks | No |
| Qiao et al. [52] | Ischemic stroke (Phase 1/2) |
UC | 6 | 0 | 56.17 (3–85) |
IVIV + IC | IV:MSC 0.5 × 106/kg IC:MSC 5 × 106 cells NSPC 6 × 106 cells at one-week interval |
4 or 1 + 3 |
Improvement in the neurological functions and ADL after 3, 12, 24 months | Fever, dizziness |
| Jiang et al. [53] | Ischemic and hemorrhagic stroke | UC | 4 | 0 | 40–59 | IA (intra-arterial) via catheterization | 2 × 107 cells | 1 | Motor functional recovery and improvement in the ADL after 3 and 6 months | No |
| Bhasin et al. [50] | Ischemic stroke | BM | 20 MSC6 MNC14 |
20 | 45.1 | IV | 5–6 × 107 cells | 1 | Improvement in the ADL after 8 and 24 weeks |
No |
| Honmou et al. [51] | Ischemic stroke (Phase 1) |
BM | 12 | 0 | 59.2 (41–73) |
IV | 0.6–1.8 × 108 cells | 1 | Incremental daily rate of change in the disability scales during 12 months |
Fever, nausea, itching |
IV, intravenous injection; IT, intrathecal injection; IC, intracranial; BM, bone marrow; UC, umbilical cord.